


# CLAIMS

What is claimed is:

5

1. A compound of Formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

10

R¹ is independently selected from:

C₅ or C₆ cycloalkyl-(C₁-C₈ alkylene);

Substituted C₅ or C₆ cycloalkyl-(C₁-C₈ alkylene);

C₈-C₁₀ bicycloalkyl-(C₁-C₈ alkylene);

Substituted C₈-C₁₀ bicycloalkyl-(C₁-C₈ alkylene);

15

5- or 6-membered heterocycloalkyl-(C₁-C₈ alkylene);

Substituted 5- or 6-membered heterocycloalkyl-(C₁-C₈ alkylene);

8- to 10-membered heterobicycloalkyl-(C₁-C₈ alkylene);

Substituted 8- to 10-membered heterobicycloalkyl-(C₁-C₈ alkylene);

Phenyl-(C₁-C₈ alkylene);

20

Substituted phenyl-(C₁-C₈ alkylene);

Naphthyl-(C₁-C₈ alkylene);

Substituted naphthyl-(C₁-C₈ alkylene);

5- or 6-membered heteroaryl-(C₁-C₈ alkylene);

Substituted 5- or 6-membered heteroaryl-(C₁-C₈ alkylene);

25

8- to 10-membered heterobiaryl-(C₁-C₈ alkylene);

Substituted 8- to 10-membered heterobiaryl-(C₁-C₈ alkylene);

Phenyl;

Substituted phenyl;

Naphthyl;

30

Substituted naphthyl;

5- or 6-membered heteroaryl;

Substituted 5- or 6-membered heteroaryl;  
8- to 10-membered heterobiaryl; and  
Substituted 8- to 10-membered heterobiaryl;

R<sup>2a</sup> is independently selected from:

- 5           H;  
          C<sub>1</sub>-C<sub>6</sub> alkyl;  
          Phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Substituted phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
10          Substituted naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Substituted 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Substituted 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
15          Phenyl-O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Substituted phenyl-O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Phenyl-S-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Substituted phenyl-S-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Phenyl-S(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
20          Substituted phenyl-S(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);  
          Phenyl-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl); and  
          Substituted phenyl-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

R<sup>2b</sup> is H or C<sub>1</sub>-C<sub>6</sub> alkyl; or

R<sup>2a</sup> and R<sup>2b</sup> are taken together with the carbon atom to which they are both bonded

- 25          to form a group selected from:

          C(O);  
          C(NR<sup>2</sup>);  
          C(S); and  
          C(CR<sup>2</sup>);

- 30          R<sup>2</sup> is independently selected from:

          H;  
          C<sub>1</sub>-C<sub>6</sub> alkyl;  
          Phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;

- Substituted phenyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- Naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- Substituted naphthyl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- 5 Substituted 5- or 6-membered heteroaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- Substituted 8- to 10-membered heterobiaryl-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- Phenyl-O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- Substituted phenyl-O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- 10 Phenyl-S-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- Substituted phenyl-S-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- Phenyl-S(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- Substituted phenyl-S(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- Phenyl-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl); and
- 15 Substituted phenyl-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);

Each substituted R<sup>1</sup>, R<sup>2a</sup>, and R<sup>2</sup> group contains from 1 to 4 substituents, each independently on a carbon or nitrogen atom, independently selected from:

- C<sub>1</sub>-C<sub>6</sub> alkyl;
- CN;
- 20 CF<sub>3</sub>;
- HO;
- (C<sub>1</sub>-C<sub>6</sub> alkyl)-O;
- (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(O)<sub>2</sub>;
- H<sub>2</sub>N;
- 25 (C<sub>1</sub>-C<sub>6</sub> alkyl)-N(H);
- (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>-N;
- (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)O-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)O-(1- to 8-membered heteroalkylenyl)<sub>m</sub>;
- (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)N(H)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- 30 (C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)N(H)-(1- to 8-membered heteroalkylenyl)<sub>m</sub>;
- H<sub>2</sub>NS(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl);
- (C<sub>1</sub>-C<sub>6</sub> alkyl)-N(H)S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;
- (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>-NS(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;

3- to 6-membered heterocycloalkyl-(G)<sub>m</sub>;

Substituted 3- to 6-membered heterocycloalkyl-(G)<sub>m</sub>;

5- or 6-membered heteroaryl-(G)<sub>m</sub>; and

Substituted 5- or 6-membered heteroaryl-(G)<sub>m</sub>;

5 (C<sub>1</sub>-C<sub>6</sub> alkyl)-S(O)<sub>2</sub>-N(H)-C(O)-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>; and

(C<sub>1</sub>-C<sub>6</sub> alkyl)-C(O)-N(H)-S(O)<sub>2</sub>-(C<sub>1</sub>-C<sub>8</sub> alkylenyl)<sub>m</sub>;

wherein each substituent on a carbon atom may further be independently selected from:


Halo; and

10 HO<sub>2</sub>C;

wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C=O;

wherein two adjacent, substantially sp<sup>2</sup> carbon atoms may be taken together with a diradical substituent to form a cyclic diradical selected from:

15



R is H or C<sub>1</sub>-C<sub>6</sub> alkyl;

G is CH<sub>2</sub>; O, S, S(O); or S(O)<sub>2</sub>;

m is an integer of 0 or 1;

Y<sup>1</sup> is C(O), O, N-R<sup>3a</sup>, S, S(O), or S(O)<sub>2</sub>;

5 Y<sup>2</sup> is C(H)R<sup>3</sup>, C(O), S, S(O), or S(O)<sub>2</sub>; or

When R<sup>2b</sup> is not taken together with R<sup>2a</sup> as described above, R<sup>2b</sup> and Y<sup>2</sup> may be taken together with the carbon atom to which they are both bonded to form

C=C(R<sup>3</sup>);

Y<sup>3</sup> is C(H)(R<sup>4</sup>), N(R<sup>4</sup>), O, S, S(O), or S(O)<sub>2</sub>;

10 R<sup>3a</sup>, R<sup>3</sup>, and R<sup>4</sup> are independently selected from the groups:

H;

CH<sub>3</sub>;

CH<sub>3</sub>O;

CH=CH<sub>2</sub>;

15 HO;

CF<sub>3</sub>;

CN;

HC(O);

CH<sub>3</sub>C(O);

20 HC(NOH);

H<sub>2</sub>N;

(CH<sub>3</sub>)-N(H);

(CH<sub>3</sub>)<sub>2</sub>-N;

H<sub>2</sub>NC(O);

25 (CH<sub>3</sub>)-N(H)C(O);

(CH<sub>3</sub>)<sub>2</sub>-NC(O); and

wherein R<sup>3a</sup>, R<sup>3</sup>, or R<sup>4</sup> are bonded to carbon, R<sup>3a</sup>, R<sup>3</sup>, or R<sup>4</sup> may further independently be halo or CO<sub>2</sub>H;







wherein 2 substituents may be taken together with a carbon atom to which they are both bonded to form the group C=O;

30 R<sup>5</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, H<sub>2</sub>N, HO, or halo;


n is an integer of from 0 to 3;

Q is selected from:

- OC(O);  
 CH(R<sup>6</sup>)C(O);  
 OC(NR<sup>6</sup>);  
 CH(R<sup>6</sup>)C(NR<sup>6</sup>);  
 5 N(R<sup>6</sup>)C(O);  
 N(R<sup>6</sup>)C(S);  
 N(R<sup>6</sup>)C(NR<sup>6</sup>);  
 N(R<sup>6</sup>)CH<sub>2</sub>;  
 SC(O);  
 10 CH(R<sup>6</sup>)C(S);  
 SC(NR<sup>6</sup>);  
 trans-(H)C=C(H);  
 cis-(H)C=C(H);  
 C≡C;  
 15 CH<sub>2</sub>C≡C;  
 C≡CCH<sub>2</sub>;  
 CF<sub>2</sub>C≡C; and  
 C≡CCF<sub>2</sub>;



; and



20

Each R<sup>6</sup> independently is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl; 3- to 6-membered heterocycloalkyl; phenyl; benzyl; or 5- or 6-membered heteroaryl;

X is O, S, N(H), or N(C<sub>1</sub>-C<sub>6</sub> alkyl);

Each V is independently C(H) or N;

wherein each C<sub>8</sub>-C<sub>10</sub> bicycloalkyl is a bicyclic carbocyclic ring that contains 8-, 9-, or 10-member carbon atoms which are 5,5-fused, 6,5-fused, or 6,6-fused bicyclic rings, respectively, and wherein the ring is saturated or optionally contains one carbon-carbon double bond;

5 wherein each 8- to 10-membered heterobicycloalkyl is a bicyclic ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O)<sub>2</sub>, 1 N, 4 N(H), and 4 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is  
10 saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond, and wherein the heterobicycloalkyl is a 5,5-fused, 6,5-fused, or 6,6-fused bicyclic ring, respectively,

wherein each heterocycloalkyl is a ring that contains carbon atoms and from 1 to 4 heteroatoms independently selected from 2 O, 1 S, 1 S(O), 1 S(O)<sub>2</sub>, 1 N, 4  
15 N(H), and 4 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and wherein when two O atoms or one O atom and one S atom are present, the two O atoms or one O atom and one S atom are not bonded to each other, and wherein the ring is saturated or optionally contains one carbon-carbon or carbon-nitrogen double bond;

wherein each 5-membered heteroaryl contains carbon atoms and from 1 to 4  
20 heteroatoms independently selected from 1 O, 1 S, 1 N(H), 1 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and 4 N, and each 6-membered heteroaryl contains carbon atoms and 1 or 2 heteroatoms independently selected from N, N(H), and N(C<sub>1</sub>-C<sub>6</sub> alkyl), and 5- and 6-membered heteroaryl are monocyclic rings;

wherein each heterobiaryl contains carbon atoms and from 1 to 4 heteroatoms  
25 independently selected from 1 O, 1 S, 1 N(H), 1 N(C<sub>1</sub>-C<sub>6</sub> alkyl), and 4 N, and where the 8-, 9-, and 10-membered heterobiaryl are 5,5-fused, 6,5-fused, and 6,6-fused bicyclic rings, respectively, and wherein at least 1 of the 2 fused rings of a bicyclic ring is aromatic, and wherein when the O and S atoms both are present, the O and S atoms are not bonded to each  
30 other;

wherein with any (C<sub>1</sub>-C<sub>6</sub> alkyl)<sub>2</sub>-N group, the C<sub>1</sub>-C<sub>6</sub> alkyl groups may be optionally taken together with the nitrogen atom to which they are attached to form a 5- or 6-membered heterocycloalkyl; and

wherein each group and each substituent recited above is independently selected.

2. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein  $Y^1$  and  $Y^2$  each are  $C(=O)$ .

5

3. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein one of  $Y^1$  and  $Y^2$  is  $C(=O)$  and the other of  $Y^1$  and  $Y^2$  is  $S(O)_2$ .

10

4. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is  $N(R^6)C(O)$ .

5. The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein Q is  $C\equiv C$ .

15

6. The compound according to any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein  $R^1$  is independently selected from:

Phenyl-( $C_1$ - $C_8$  alkylene);

Substituted phenyl-( $C_1$ - $C_8$  alkylene);

20

5- or 6-membered heteroaryl-( $C_1$ - $C_8$  alkylene);

Substituted 5- or 6-membered heteroaryl-( $C_1$ - $C_8$  alkylene);

8- to 10-membered heterobiaryl-( $C_1$ - $C_8$  alkylene); and

Substituted 8- to 10-membered heterobiaryl-( $C_1$ - $C_8$  alkylene); and

$R^2$  is independently selected from:

25

Phenyl-( $C_1$ - $C_8$  alkylene) $_m$ ;

Substituted phenyl-( $C_1$ - $C_8$  alkylene) $_m$ ;

5- or 6-membered heteroaryl-( $C_1$ - $C_8$  alkylene) $_m$ ;

Substituted 5- or 6-membered heteroaryl-( $C_1$ - $C_8$  alkylene) $_m$ ;

8- to 10-membered heterobiaryl-( $C_1$ - $C_8$  alkylene) $_m$ ; and

30


Substituted 8- to 10-membered heterobiaryl-( $C_1$ - $C_8$  alkylene) $_m$ ;

wherein m is an integer of 0 or 1; and

wherein each group and each substituent is independently selected.

7. A compound of Formula II





II


or a pharmaceutically acceptable salt thereof.

8. The compound of Formula II according to Claim 7, selected from:

- 5 1-Methyl-3-[1-phenyl-meth-(Z)-ylidene]-6-(3-phenyl-prop-1-ynyl)-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazine;
- 6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-1-methyl-3-[1-phenyl-meth-(Z)-ylidene]-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazine;
- 3-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 10 3-[1-(3,4-Difluoro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(3,4-Dichloro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 15 3-[1-(3-Fluoro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(3-Chloro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(4-Chloro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 20 3-[1-(3-Chloro-4-fluoro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(4-Chloro-3-fluoro-phenyl)-meth-(Z)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 25 1-Methyl-3-[1-phenyl-meth-(E)-ylidene]-6-(3-phenyl-prop-1-ynyl)-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazine;

- 6-[3-(4-Methoxy-phenyl)-prop-1-ynyl]-1-methyl-3-[1-phenyl-meth-(E)-ylidene]-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazine;
- 3-[1-(3-Fluoro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 5 3-[1-(3,4-Difluoro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(3,4-Dichloro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 10 3-[1-(3-Fluoro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(3-Chloro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 3-[1-(4-Chloro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 15 3-[1-(3-Chloro-4-fluoro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one; and
- 3-[1-(4-Chloro-3-fluoro-phenyl)-meth-(E)-ylidene]-6-[3-phenyl-prop-1-ynyl]-1-methyl-2-oxo-2,3-dihydro-1H-2λ<sup>4</sup>-benzo[c][1,2]thiazin-4-one;
- 20 or a pharmaceutically acceptable salt thereof.

9. A compound of Formula III



III

- 25 or a pharmaceutically acceptable salt thereof.

10. The compound of Formula III according to Claim 9, selected from:

- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-benzo[c][1,2]thiazine  
-6-carboxylic acid benzylamide;
- 3-Benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-benzo[c][1,2]thiazine  
-6-carboxylic acid 4-methoxy-benzylamide;
- 5 3-(3-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3,4-Difluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3,4-Dichloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
10 benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 15 3-(4-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3-Chloro-4-fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(4-Chloro-3-fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
20 benzo[c][1,2]thiazine -6-carboxylic acid 4-methoxy-benzylamide;
- 3-(3-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;
- 3-(3,4-Difluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;
- 25 3-(3,4-Dichloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;
- 3-(3-Fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;
- 3-(3-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
30 benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;

3-(4-Chloro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;  
3-(3-Chloro-4-fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide; and  
5 3-(4-Chloro-3-fluoro-benzyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-2λ<sup>4</sup>-  
benzo[c][1,2]thiazine -6-carboxylic acid 4-fluoro-benzylamide;  
or a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition, comprising a compound according to  
10 Claim 1, or a pharmaceutically acceptable salt thereof, admixed with a  
pharmaceutically acceptable carrier, excipient, or diluent.
12. The pharmaceutical composition according to Claim 11, comprising a  
compound according to Claim 9 or 10, or a pharmaceutically acceptable salt  
15 thereof, admixed with a pharmaceutically acceptable carrier, excipient, or diluent.
13. A method for treating arthritis, comprising administering to a patient  
suffering from an arthritis disease a nontoxic antiarthritic effective amount of a  
compound according to Claim 1, or a pharmaceutically acceptable salt thereof.  
20
14. The method according to Claim 13, wherein the arthritis is osteoarthritis or  
rheumatoid arthritis.
15. The method according to Claim 14, wherein the compound according to  
25 Claim 1 is a compound according to Claim 9 or 10.